Small Animal Imaging Lab

项目摘要 小动物影像实验室 小动物成像实验室（SAIL）的首要目标是提供最先进的成像资源， Moffitt成员使用啮齿动物癌症模型进行的基础和转化临床前研究。SAIL提供一个 多种多样的多模态成像能力（例如，MRI、CT、SPECT、生物发光等）并提供预- 临床放射性药物能力。总的来说，这些技术促进了肿瘤发展的研究， 使用定量成像在动物模型中观察疾病的进展、转移和对治疗的反应。SAIL提供 以高空间分辨率检测功能、代谢和解剖学变化，包括缺氧，pH， 对细胞密度、血流和代谢的时间敏感性。数据传输管道已经建立 其中成像数据被传输到QIC以进行图像特征提取和高级图像分析， 原位肿瘤生物学的综合评估。SAIL活动分为三个具体目标： 目标1：协助会员进行实验设计、图像数据采集和分析以及手稿和 准备补助金。 目标2：提供和扩展尖端的体内和体外成像和分析技术，用于研究 涉及小动物癌症模型。 目标3：提供关于小动物成像技术的深入培训和教育机会 为会员提供服务。 SAIL使会员能够进行复杂的成像实验，支持高影响力的科学， 临床前动物模型，这对于理解癌症的生物学和复杂的反应至关重要。 不同的肿瘤类型，免疫系统和治疗宿主的生理学。小动物成像 为未来的研究设计提供信息，可用于联合临床试验的分析，也为设计和 实施临床试验。最后，由于SAIL提供的大多数模式都可以在 在临床上，动物肿瘤模型的结果可以很容易地转化为临床试验和临床实践。 自2016年以来，SAIL的使用量增加了15%，并支持了28个成员出版物，其中包括3个出现在 高影响力期刊（IF >10）。在20财年，SAIL在五个项目中的四个项目中支持了30名成员（CBE 33%， CE 3%，MM 27%，IO 37%），其中85%的成员持有同行评审资金。占93% 所有的SAIL使用。在未来五年内，SAIL将扩大对参与研究的成员的支持， 通过扩展其服务、设备和专家人员，开展体内代谢和核成像。这将 将SAIL定位为支持以代谢为重点的CCSG计划和许多教师的发展 在这个竞技场有研究项目的人。

PROJECT SUMMARY SMALL ANIMAL IMAGING LAB The overarching goal of the Small Animal Imaging Lab (SAIL) is to provide state-of-the art imaging resources to Moffitt Members for their basic and translational preclinical studies using rodent cancer models. SAIL offers a wide array of multimodality imaging capabilities (e.g., MRI, CT, SPECT, bioluminescence etc.) and provides pre- clinical radiopharmaceutical capabilities. Collectively, these technologies facilitate study of tumor development, progression, metastasis and the response to therapy in animal models using quantitative imaging. SAIL provides detection at high spatial resolution of functional, metabolic, and anatomical changes including hypoxia, pH, temporal sensitivity to cellular density, blood flow, and metabolism. A data transfer pipeline has been established where imaging data is transferred to QIC for image feature extraction and advanced image analysis to generate an integrated assessment of tumor biology in situ. SAIL activities are organized into three Specific Aims: Aim 1: To assist Members in experimental design, image data acquisition and analysis, and manuscript and grant preparation. Aim 2: To provide and expand cutting-edge in vivo and ex vivo imaging and analytical technologies for research involving small animal cancer models. Aim 3: To provide in-depth training and educational opportunities regarding small animal imaging technologies and approaches for Members. SAIL enables Members to perform sophisticated imaging experiments that support high impact science using preclinical animal models, which are critical for understanding the biology of cancer and the complex responses of distinct tumor types, the immune system and the physiology of the host to therapy. Small animal imaging informs future research design, can be used for the analysis of co-clinical trials, and also informs the design and implementation of clinical trials. Finally, as most of the modalities that are provided by SAIL are available in the clinic, results with animal tumor models can be readily translated into clinical trials and clinical practice. Since 2016, SAIL usage has increased by 15% and has supported 28 Member publications including 3 appearing in a high impact journal (IF >10). In FY20, SAIL supported 30 Members in four of the five Programs (CBE 33%, CE 3%, MM 27%, IO 37%) with 85% of those Members holding peer reviewed funding. This represented 93% of all SAIL usage. Over the next five years, SAIL will expand support for Members engaging in studies requiring in vivo metabolic and nuclear imaging through expansion of its services, equipment, and expert staff. This will position SAIL well to support the development of a metabolism focused CCSG Program and the many faculty who have research programs in this arena.